Trial Profile
A multicentre, observational, retrospective study analysing efficacy and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Mar 2020
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Rivoceranib (Primary)
- Indications Alveolar soft part sarcoma; Cancer metastases; Clear cell sarcoma; Dermatofibrosarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Neuroectodermal tumours; Osteosarcoma; Ovarian cancer; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2020 New trial record
- 25 Feb 2020 Results assessing effectiveness of Anlotinib and Rivoceranib and associated AEs based on the histological type of sarcom, published in the Investigational New Drugs